A Critical Deadline Looms for CureVac Shareholders

CureVac NL0015436031

Time is running out for investors holding CureVac stock. The impending acquisition by its Mainz-based rival, BioNTech, has entered its final, decisive stage, and the window for shareholder action is closing rapidly. Failure to act by a key operational deadline could result in significant and avoidable financial penalties.

While the official exchange offer period extends into Wednesday, the practical deadline for shareholders is significantly earlier. To ensure their holdings are processed in time, investors must instruct their banks or brokers to tender their CureVac shares no later than 6:00 PM ET on Tuesday, December 2, 2025.

This urgency stems from the procedural requirements of depositories. The shareholder vote on November 25, which approved the deal with a majority exceeding 99%, set the stage for this final phase. Under the terms of the offer, each CureVac share will be exchanged for 0.05363 American Depositary Shares (ADS) of BioNTech.

A Costly Oversight: The Tax Trap

Missing this deadline is more than a procedural error; it is a potentially expensive mistake. Shares not tendered in time will be subject to a subsequent corporate reorganization. In this scenario, remaining shareholders face a direct financial hit: a 15% Dutch withholding tax on the liquidation payout. This charge is entirely avoidable by participating in the current exchange offer.

Market sentiment appears to have fully priced in the transaction's completion. Trading at €4.66 at the start of the week, CureVac's stock is hovering near its 52-week high of €4.83, indicating strong market confidence that the merger will proceed.

Merging from a Position of Financial Strength

The union comes as CureVac reports a solid financial foundation, despite recent headwinds. The Tübingen-based firm's third-quarter 2025 revenue fell sharply to €54.1 million, primarily due to the absence of a one-time milestone payment from GSK that had bolstered the previous year's figures.

However, the underlying financials remain robust. The company reported earnings per share of €1.21 and holds a strong cash position exceeding €416 million. These substantial reserves will now support the integration process, enabling the combined entity to accelerate mRNA technology development and resolve ongoing patent disputes.

The imperative for investors this Monday is unambiguous. Immediate action is required. Shareholders must verify their brokerage communications and ensure instructions are submitted before Tuesday's cutoff. Procrastination may lead to unnecessary tax liabilities, leaving some investors at a disadvantage as the merged company moves forward.